# PEACE6-Vulnerable (NCT04916613)

> ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

No report yet. It can be ordered.

- Drugs tested: darolutamide
- Indication: de novo metastatic prostate cancer, vulnerable functional ability

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04916613
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: UNICANCER
- Conditions: Prostate Cancer Metastatic
- Interventions: Darolutamide 300 mg; Placebo; Androgen deprivation therapy
- Enrollment: 300
- Primary outcome: Radiographic progression-free survival

## Indexed commentary on PEACE6-Vulnerable so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=peace6-vulnerable-nct04916613